Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
P/S (TTM)
0.2
EV / FCF (TTM)
11.0
Procaps Group S.A., established in Luxembourg in 1977, functions as a global pharmaceutical enterprise dedicated to the creation, production, and distribution of a broad spectrum of pharmaceutical solutions. The company manufactures and markets branded prescription medications addressing diverse therapeutic needs, including women's health, pain management, dermatological conditions, digestive disorders, growth and development, cardiovascular care, vision health, central nervous system ailments, and respiratory issues. In addition to prescription drugs, Procaps supplies a suite of products for hospital use, encompassing antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Its consumer healthcare division offers an extensive portfolio of over-the-counter (OTC) products across approximately eight primary therapeutic areas such as gastrointestinal health, skincare, cough and cold remedies, pain relievers, urological support, and a variety of vitamins, minerals, and dietary supplements. These offerings cover specific categories like anti-infectives, cardiovascular health, hormonal treatments, metabolic and endocrine support, nervous system medications, ophthalmic solutions, osteoarticular products, and more. Complementing its drug offerings, Procaps provides various diabetes management solutions, including blood glucose meters, telemonitoring devices, oral anti-diabetic medications, cosmeceuticals, and insulin delivery systems. The company also extends its expertise to third-party pharmaceutical companies through contract drug development and manufacturing services, with a particular specialization in soft gelatin capsule technologies.
sofgenpharma.comNo one on the platform currently holds PROC.
No tracked institution reports a position in PROC as of their last filing.
No one on the platform has traded PROC yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 17.5% | — | — | — | ||
| Rev. Growth % | 0.0% | |||||
| Profit Margin % | 10.4% | |||||
| Free Cash Flow Margin % | -4.3% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +10.1% on the P/E track.
At today's price, your expected annual return is +16.1% on the P/E track.
At today's price, your expected annual return is +20.0% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.0B | +1240.1% | $0.60 | $0.60–$0.60 | 1.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2023-12-26 | $0.05 | $0.08 | +60.0% |
| 2023-11-14 | $0.05 | $0.08 | +60.0% |
| 2023-09-05 | $0.06 | $0.27 | +350.0% |
| 2023-06-05 | $-0.04 | $0.07 | +275.0% |
| 2023-05-12 | $0.01 | $0.10 | +900.0% |
| 2022-11-14 | $0.13 | $0.22 | +69.2% |
| $109M |
| — |
| OPTNOptiNose, Inc. | $9.60 | +0.00% | $97M | — |
| RVLPRVL Pharmaceuticals plc | $0.03 | -32.05% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
https://www.marketbeat.com/earnings/reports/2026-6-25-procaps-group-sa-stock-1/ $PROC ProCook Group Earnings Transcript
View on StockTwits ↗
$PROC stockholders filed a claim against Procaps for allegedly hiding related-party loans, misclassifying transactions, and facing scrutiny over delayed filings, a withdrawn Deloitte audit, and a Nasdaq delisting notice. You can join this case to be notified about any new information: https://11th.com/cases/procaps-attorney-investigation?utm_source=tradingview&utm_medium=referral&utm_campaign=case&utm_content=09182025_1
View on StockTwits ↗
$PROC $EVOK Congratulations Bulls! Consider moving profits to $DGXX
View on StockTwits ↗
Big volume spikes spotted in $PROC $EQ $ZCMD $CVAC $HIND today. keeping on the radar!
View on StockTwits ↗
$PROC Expert Market today. I can not believe how it ran up yesterday with this looming.
View on StockTwits ↗$PROC Probably moves to expert market tomorrow since they are delinquent on their 20F from 2023. OTC sometimes gives one day before the move to expert I am guessing to allow people to sell that want out before the move. The last time this happened for $SPI now SPIEF https://stocktwits.com/Trding/message/600048638
View on StockTwits ↗
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Procaps Group SA. Is that bullish or bearish? $PROC #Procaps #RsiOversold #NASDAQ
View on StockTwits ↗
$PROC with a good PR before years end we should be around 4.40-4.90
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.